| Patient | Mahalia Jackson |
|---|---|
| Date of birth | 1973-10-26 |
| Identifiers | MRN HR-ML035-SYN; SSN (made up) 000-35-4692 |
| Document date | 2026-05-11 |
| Author | Beatrice Fontenot, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review after nine weeks of treatment. [S]
Ms. Jackson returns nine weeks after starting prednisone and methotrexate. The electrophysiology study induced sustained ventricular tachycardia, and a dual-chamber defibrillator was placed the next day; the wound has healed and she has had no shocks. The remote transmission last week showed two short runs of ventricular tachycardia in March and none since. She climbs two flights before stopping, the cough has gone, and the palpitations are rare. She has had a large appetite, gained weight, and sleeps poorly on prednisone. Home glucose readings are 100 to 130 mg/dL. She has had no mouth sores, nausea or infections on methotrexate, and drinks no alcohol. The final EBUS cultures were negative. No methotrexate blood tests have been done since she started. She is eager to sing again and has concerts offered from the end of May. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Device | Dual-chamber defibrillator since the electrophysiology study; no shocks; two runs of ventricular tachycardia in March, none since |
| Symptoms | Two flights of stairs; cough gone; palpitations rare |
| Steroid effects | Large appetite, weight up 2.8 kg, poor sleep; home glucose 100 to 130 mg/dL |
| Methotrexate | 15 mg weekly; no mouth sores or nausea; no blood tests since starting |
| Work | Concerts offered from the end of May |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Large appetite; weight 94.0 kg; no fever |
| Respiratory | Negative | Cough gone; breathless only on the second flight |
| Cardiovascular | Negative | Palpitations rare; no shocks, fainting or ankle swelling |
| Ears, nose, mouth, and throat | Negative | No mouth sores or thrush; voice strong |
| Endocrine | Positive | Home glucose 100 to 130 mg/dL; no thirst |
| Psychiatric | Positive | Poor sleep on prednisone; mood good; PHQ-9 5; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning | 40 mg each morning | Oral route | 2026-03-09 to 2026-05-11 | completed | S |
| Prednisone 10 mg oral tablet, three tablets (30 mg) by mouth each morning for four weeks | 30 mg each morning for four weeks | Oral route | 2026-05-11 to 2026-06-08 | completed | S |
| Methotrexate 2.5 mg oral tablet, six tablets (15 mg) by mouth once a week on Sundays | 15 mg once weekly | Oral route | 2026-03-09 to 2026-05-11 | completed | S |
| Methotrexate 2.5 mg oral tablet, eight tablets (20 mg) by mouth once a week on Sundays | 20 mg once weekly | Oral route | 2026-05-11 | active | S |
| Folic acid 1 mg oral tablet, one tablet by mouth daily | One tablet daily | Oral route | 2026-03-09 | active | S |
| Atovaquone 750 mg/5 mL oral suspension, 1500 mg (10 mL) by mouth once daily with food | 1500 mg once daily with food | Oral route | 2026-03-09 to 2026-07-06 | completed | S |
| Alendronate 70 mg oral tablet, one tablet by mouth once weekly on rising, with a full glass of water, staying upright for 30 minutes | One tablet once weekly | Oral route | 2026-03-16 | active | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily | One tablet daily | Oral route | 2026-03-09 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet by mouth daily | One tablet daily | Oral route | 2026-05-11 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-11 | Body height | 170 | cm | S |
| 2026-05-11 | Body weight | 94 | kg | S |
| 2026-05-11 | Body mass index (BMI) [Ratio] | 32.5 | kg/m2 | S |
| 2026-05-11 | Systolic blood pressure | 138 | mm[Hg] | S |
| 2026-05-11 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-05-11 | Heart rate | 66 | /min | S |
| 2026-05-11 | Respiratory rate | 16 | /min | S |
| 2026-05-11 | Body temperature | 36.6 | Cel | S |
| 2026-05-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-11 | Hemoglobin [Mass/volume] in Blood | 13.1 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-05-11 | Leukocytes [#/volume] in Blood by Automated count | 9.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-05-11 | Lymphocytes [#/volume] in Blood by Automated count | 1.2 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 2026-05-11 | Platelets [#/volume] in Blood by Automated count | 262 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-05-11 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-11 | Potassium [Moles/volume] in Serum or Plasma | 3.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-11 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-05-11 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 75 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-11 | Glucose [Mass/volume] in Serum or Plasma | 118 | mg/dL | 70-99 mg/dL | High | S |
| 2026-05-11 | Calcium [Mass/volume] in Serum or Plasma | 9.6 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-05-11 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-35 U/L | Normal | S |
| 2026-05-11 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 8-35 U/L | Normal | S |
| 2026-05-11 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 96 | U/L | 35-104 U/L | Normal | S |
| 2026-05-11 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-05-11 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.3 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes | High | S |
| 2026-05-11 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 24 | ng/mL | 30-100 ng/mL | Low | S |
| 2026-05-11 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 140 | pg/mL | <=125 pg/mL | High | S |
| 2026-05-11 | FVC measured/predicted | 84 | % | >=80% | Normal | S |
| 2026-05-11 | FEV1 measured/predicted | 85 | % | >=80% | Normal | S |
| 2026-05-11 | FEV1/FVC | 80 | % | >=70% | Normal | S |
| 2026-05-11 | Diffusion capacity.carbon monoxide/Predicted | 70 | % | >=80% | Low | S |
| 2026-05-11 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S |
Vital signs recorded on 2026-05-11; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 94.0 kg; blood pressure 138/86, pulse 66 and regular |
| Respiratory | Clear to auscultation |
| Cardiovascular | Regular rhythm; no murmur; defibrillator pocket healed without swelling or tenderness |
| Mouth | No thrush or ulcers |
| Skin | Mild facial fullness; no bruising or infection |
| Psychiatric | Cheerful, impatient to sing |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness on exertion and a dry cough for three months, worse on tour, with tiredness and chest tightness; she can no longer hold long phrases; bilateral hilar lymph node enlargement on today's chest radiograph; granulomas were reported at an abdominal operation twelve years ago, with no pathology report available: sarcoidosis must be confirmed by tissue and other causes excluded | resolved | confirmed | R06.09 | S — Synthetic presenting problem anchored to the documented breathlessness during performances and the 1952 granulomas. Superseded by the tissue diagnosis at the consultation. |
| Palpitations with two spells of light-headedness while singing; ECG today: sinus rhythm with first-degree atrioventricular block (PR 240 ms) and frequent ventricular ectopic beats: cardiac involvement must be looked for | resolved | confirmed | R00.2 | S — Synthetic finding; superseded when cardiac sarcoidosis was diagnosed. |
| Hypercalcemia: calcium 10.8 mg/dL with a high 1,25-dihydroxyvitamin D and a low 25-hydroxyvitamin D, while taking an over-the-counter calcium and vitamin D supplement; creatinine slightly raised | resolved | confirmed | E83.52 | S — Synthetic finding; resolved on treatment. |
| Pulmonary sarcoidosis with hilar and mediastinal lymph node involvement (Scadding stage II), confirmed by non-necrotizing granulomas on EBUS-guided lymph node aspiration with negative stains and cultures; mild restriction and reduced diffusing capacity; synthetic modern detail linked to her documented sarcoidosis | active | confirmed | D86.2 | S — Synthetic histology, stage and lung function; her biographer reports a diagnosis of sarcoidosis after granulomas were found at an operation (D, probable). |
| Cardiac sarcoidosis: first-degree atrioventricular block, ventricular ectopy (6 percent of beats) with nonsustained ventricular tachycardia, left ventricular ejection fraction 47 percent, patchy late gadolinium enhancement of the basal septum and inferolateral wall, and matching focal FDG uptake on PET; synthetic modern detail linked to the documented private account that sarcoidosis was in her heart | active | confirmed | D86.85 | S — Synthetic cardiac findings; the account that her doctors told her sarcoidosis was in her heart rests on her biographer (D, probable), and the interpretation of her later heart disease is R. |
| Long-term systemic glucocorticoid treatment for sarcoidosis, with bone, glucose, blood pressure, infection and eye risks to manage | active | confirmed | Z79.52 | S — Synthetic treatment status. |
| Dual-chamber implantable cardioverter-defibrillator, placed after sustained monomorphic ventricular tachycardia was induced at electrophysiology study; remote monitoring | active | confirmed | Z95.810 | S — Synthetic device status after the synthetic implant. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Spirometry and diffusing capacity (FVC, FEV1, FEV1/FVC, DLCO) | At diagnosis, three months after starting treatment, then every three to six months while treatment changes | Completed today | FVC 84 percent, FEV1 85 percent, FEV1/FVC 80 percent, DLCO 70 percent of predicted |
| Laboratory | Methotrexate safety: blood count, liver tests and creatinine | Before starting; every two to four weeks for the first three months; then every eight to twelve weeks | Deferred | A deviation: the blood count, liver tests and creatinine due two to four weeks after methotrexate began were not done, because no laboratory order was placed for the long gap between visits. No harm resulted: today hemoglobin 13.1 g/dL, white cells 9.8 (raised by prednisone), lymphocytes 1.2, platelets 262, ALT 31, AST 28, alkaline phosphatase 96 U/L, albumin 4.1 g/dL, creatinine 0.92 mg/dL and eGFR 75 are normal. Corrective action: standing orders every four weeks until twelve weeks and then every eight to twelve weeks, at a laboratory near home or on tour, with a reminder to her and to the clinic |
| Laboratory | Serum calcium | At diagnosis, then at each treatment visit while it was raised or vitamin D is given | Completed today | 9.6 mg/dL, normal |
| Laboratory | Electrolytes | At each visit on glucocorticoids | Completed today | Sodium 139, potassium 3.9 mmol/L |
| Laboratory | 25-hydroxyvitamin D | Before replacement and after it starts | Completed today | 24 ng/mL; replacement started now that calcium is normal |
| Laboratory | Glucose and A1c on glucocorticoids | At each visit; A1c every three months | Completed today | Glucose 118 mg/dL; A1c 6.3% |
| Laboratory | NT-proBNP | At each cardiac review | Completed today | 140 pg/mL |
| Examination | Blood pressure and weight on glucocorticoids | Each visit | Completed today | 138/86 mmHg; weight 94.0 kg, up 2.8 kg |
| Imaging | Bone density (DXA) and FRAX | At the start of long-term glucocorticoids, then every one to three years | Up to date | March: femoral neck T-score -1.6; moderate risk; alendronate |
| Examination | Defibrillator check (remote and in clinic) | Remote transmissions monthly and with any symptom; clinic check every three to six months | Completed today | Remote transmission last week: two runs of nonsustained ventricular tachycardia in March, none since; no therapies; normal lead values |
| Laboratory | Exclusion of other granulomatous causes | At diagnosis | Up to date | Final mycobacterial and fungal cultures negative at eight weeks |
| Medication safety | Pneumocystis prophylaxis | While prednisone is 20 mg or more with a second immunosuppressant | Completed today | Atovaquone continues until prednisone falls below 20 mg |
| Medication safety | Vaccination on immunosuppression | Per schedule | Completed today | Hepatitis B dose 2 given today, completing the two-dose series; zoster dose 2 due in August |
| Survey | Depression screen (PHQ-9) | At diagnosis and at each phase of treatment | Completed today | PHQ-9 5 |
| Self-management | Performing and travel plan | At each visit | Completed today | Two concerts a week in the United States from the end of May, with a rest day after each; no international touring until after the August PET; voice care; travel letter and device card |
Goal progress:
Immunizations given today: Hepatitis B vaccine (adjuvanted, two-dose series), dose 2 [S]
Guideline basis: Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079 (PMID 34140301) (2021); Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305-1323 (PMID 24819193) (2014); Cheng RK, et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 2024;149(21):e1197-e1216 (PMID 38634276) (2024); Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (PMID 37845798) (2022); Singh JA, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64(5):625-639 (PMID 22473917) (methotrexate laboratory monitoring) (2012); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Methotrexate blood tests every four weeks. Remote device checks monthly. Review in mid-August after the repeat FDG-PET, echocardiogram and lung function. Call for fever, cough, breathlessness, a shock, or fainting. Next scheduled visit 2026-08-24: six months of treatment: repeat FDG-PET, steroid taper, and plans for touring. [S]